Following the ISEV2018 guidelines [40], the EV characterization showed the presence of the EV-specific markers: CD9 molecule (CD9), CD81 molecule (CD81), and Tumor Susceptibility 101 (TSG101) in our serum. This evidence concerns the gene CD81 and neoplasm.